Nihar Ranjan Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nihar Ranjan Das has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Susanta Kumar Sahu
Roland Institute of Pharmaceutical Sciences, Berhampur, Ganjam, 760010, Odisha, India
3 shared publicationsBimalendu Chowdhury
Roland Institute of Pharmaceutical Sciences, Berhampur, Ganjam, 760010, Odisha, India
2 shared publicationsRakesh Kumar Nayak
Roland Institute of Pharmaceutical Sciences, Berhampur, Ganjam, 760010, Odisha, India
2 shared publicationsZeenath Banu
Department of Pharmacology, RBVRR Women’s College of Pharmacy, Barkatpura, Hyderabad, Telangana-500027, India
2 shared publications- Zeenath Banu
Department of Pharmacology, GITAM School of Pharmacy, GITAM (Deemed to be University), Rushikonda, Visakhapatnam, India
2 shared publications Abinashi Sabyasachi Sethy
Maharaja Krushna Chandra Gajapati Medical College and Hospital
1 shared publication
Latest Publications
- 4 May 2026
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 23, 1-26
Gut Microbiota Dysbiosis in Alzheimer’s Disease and Possible Therapeutic Options
Human microbiota consists of trillions of microbial cells dominated by bacteria, which live in the human body, while the term microbiome refers to the collective genetic material of microorganisms. Among them, the gut microbiota has emerged as pivotal, producing its own metabolites, neurotransmitter precursors, and immune mediators that affect brain development and function. These signals function via the complex, bidirectional Gut–Brain Axis (GBA). This is a communication network that connects the gastrointestinal tract to the central nervous system. This axis plays an important role in the regulation of gastrointestinal homeostasis, neurodevelopment, emotional regulation, and cognitive processes. Increasing evidence suggests that microbial dysbiosis within the gastrointestinal tract is involved in the pathogenesis and progression of several neurological and neurodegenerative disorders, including mood disorders, schizophrenia, autism spectrum disorder, Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Huntington’s Disease. These insights have opened new therapeutic possibilities, and multiple microbiota-targeted interventions, such as dietary modification, prebiotics, probiotics, postbiotics, psychobiotics, antibiotics, and Fecal Microbiota Transplantation (FMT), are now being explored for their therapeutic value, especially in Alzheimer’s disease.
- 4 May 2026
- Published by Bentham Science Publishers Ltd. in Current Alzheimer Research
- Vol. 23, 1-26
Gut Microbiota Dysbiosis in Alzheimer’s Disease and Possible Therapeutic Options
Human microbiota consists of trillions of microbial cells dominated by bacteria, which live in the human body, while the term microbiome refers to the collective genetic material of microorganisms. Among them, the gut microbiota has emerged as pivotal, producing its own metabolites, neurotransmitter precursors, and immune mediators that affect brain development and function. These signals function via the complex, bidirectional Gut–Brain Axis (GBA). This is a communication network that connects the gastrointestinal tract to the central nervous system. This axis plays an important role in the regulation of gastrointestinal homeostasis, neurodevelopment, emotional regulation, and cognitive processes. Increasing evidence suggests that microbial dysbiosis within the gastrointestinal tract is involved in the pathogenesis and progression of several neurological and neurodegenerative disorders, including mood disorders, schizophrenia, autism spectrum disorder, Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Huntington’s Disease. These insights have opened new therapeutic possibilities, and multiple microbiota-targeted interventions, such as dietary modification, prebiotics, probiotics, postbiotics, psychobiotics, antibiotics, and Fecal Microbiota Transplantation (FMT), are now being explored for their therapeutic value, especially in Alzheimer’s disease.
- Open Access
- 16 April 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (4) , e70845
Capsaicin Mitigates Insulin Resistance‐Driven Prostate Hyperplasia Via IGF‐1 Signalling Modulation in HFD + STZ Rat Model
Insulin Resistance (IR) is usually associated with elevated glucose levels and hyperinsulinemia. Elevated insulin levels during IR contribute to prostate enlargement and can lead to the condition of Benign Prostatic Hyperplasia (BPH). This study investigated the effects of capsaicin, a bioactive compound derived from chilli peppers, on IR‐induced prostatic hyperplasia. High‐fat diet (HFD) combined with streptozotocin (STZ) was used to induce IR in rats. Rats subjected to HFD + STZ exhibited elevated fasting blood glucose, insulin levels and an increased Prostate weight, confirming IR‐induced prostate enlargement. Capsaicin administration significantly ameliorated fasting glucose and insulin levels, reduced prostate weight and mitigated histopathological alterations. Furthermore, capsaicin treatment downregulated IGF‐1 expression, suggesting its potential role in modulating IGF‐1 signalling involved in cellular proliferation and differentiation and reversing prostate hyperplasia. These findings open up new avenue for exploring more about capsaicin as a possible therapeutic candidate for managing IR‐induced prostatic hyperplasia.
- 16 April 2026
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 40 (4) , e70845
Open AccessCapsaicin Mitigates Insulin Resistance‐Driven Prostate Hyperplasia Via IGF‐1 Signalling Modulation in HFD + STZ Rat Model
Insulin Resistance (IR) is usually associated with elevated glucose levels and hyperinsulinemia. Elevated insulin levels during IR contribute to prostate enlargement and can lead to the condition of Benign Prostatic Hyperplasia (BPH). This study investigated the effects of capsaicin, a bioactive compound derived from chilli peppers, on IR‐induced prostatic hyperplasia. High‐fat diet (HFD) combined with streptozotocin (STZ) was used to induce IR in rats. Rats subjected to HFD + STZ exhibited elevated fasting blood glucose, insulin levels and an increased Prostate weight, confirming IR‐induced prostate enlargement. Capsaicin administration significantly ameliorated fasting glucose and insulin levels, reduced prostate weight and mitigated histopathological alterations. Furthermore, capsaicin treatment downregulated IGF‐1 expression, suggesting its potential role in modulating IGF‐1 signalling involved in cellular proliferation and differentiation and reversing prostate hyperplasia. These findings open up new avenue for exploring more about capsaicin as a possible therapeutic candidate for managing IR‐induced prostatic hyperplasia.
- 3 December 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (8) , 330
Protective effects of alkaloidal fraction of Elaeocarpus angustifolius Blume against AlCl₃-evoked neurotoxicity: insights from an in vivo model of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and neuronal degeneration. Current treatments offer limited efficacy. Elaeocarpus angustifolius Blume (Rudraksha), used traditionally in Ayurveda for neurological disorders, has shown potential for cognitive health, warranting investigation in AD models. This study aimed to evaluate the neuroprotective efficacy of an alkaloid-rich fraction of E. angustifolius (EAF) in an AlCl₃-induced rat model of AD. AD-like symptoms were induced by oral administration of AlCl₃ (100 mg/kg) for 60 days, followed by a 30-day oral treatment with EAF (200 and 400 mg/kg). Cognitive performance was assessed using the Morris water maze, elevated plus maze, novel object recognition, and locomotor activity tests. Biochemical and molecular markers were analysed, and hippocampal histopathology was conducted. AlCl₃ exposure caused significant cognitive and motor deficits, elevated Aβ1−42 and phosphorylated tau, decreased acetylcholine and dopamine, increased glutamate and NF-κB, and reduced NRF-2 expression, indicating oxidative stress and neuroinflammation. EAF treatment significantly improved behavioral outcomes, reduced Aβ1−42 and tau levels, restored neurotransmitter balance, enhanced antioxidant markers (GSH, SOD, CAT), and reduced MDA. It suppressed NF-κB and upregulated NRF-2, suggesting antioxidant and anti-inflammatory effects. Histopathological analysis confirmed hippocampal neuroprotection. EAF exhibited significant neuroprotective effects by mitigating oxidative stress, neuroinflammation, and AD-related pathologies, including amyloid accumulation and cholinergic dysfunction. These findings support the potential of EAF as a therapeutic candidate for AD prevention and management. Graphical Abstract Schematic representation summarising the mechanisms underlying the neuroprotective effects of Elaeocarpus angustifolius alkaloid-rich fraction (EAF) in AlCl₃-induced rat model of AD
- 3 December 2025
- Published by Springer Nature in Metabolic Brain Disease
- Vol. 40 (8) , 330
Protective effects of alkaloidal fraction of Elaeocarpus angustifolius Blume against AlCl₃-evoked neurotoxicity: insights from an in vivo model of Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and neuronal degeneration. Current treatments offer limited efficacy. Elaeocarpus angustifolius Blume (Rudraksha), used traditionally in Ayurveda for neurological disorders, has shown potential for cognitive health, warranting investigation in AD models. This study aimed to evaluate the neuroprotective efficacy of an alkaloid-rich fraction of E. angustifolius (EAF) in an AlCl₃-induced rat model of AD. AD-like symptoms were induced by oral administration of AlCl₃ (100 mg/kg) for 60 days, followed by a 30-day oral treatment with EAF (200 and 400 mg/kg). Cognitive performance was assessed using the Morris water maze, elevated plus maze, novel object recognition, and locomotor activity tests. Biochemical and molecular markers were analysed, and hippocampal histopathology was conducted. AlCl₃ exposure caused significant cognitive and motor deficits, elevated Aβ1−42 and phosphorylated tau, decreased acetylcholine and dopamine, increased glutamate and NF-κB, and reduced NRF-2 expression, indicating oxidative stress and neuroinflammation. EAF treatment significantly improved behavioral outcomes, reduced Aβ1−42 and tau levels, restored neurotransmitter balance, enhanced antioxidant markers (GSH, SOD, CAT), and reduced MDA. It suppressed NF-κB and upregulated NRF-2, suggesting antioxidant and anti-inflammatory effects. Histopathological analysis confirmed hippocampal neuroprotection. EAF exhibited significant neuroprotective effects by mitigating oxidative stress, neuroinflammation, and AD-related pathologies, including amyloid accumulation and cholinergic dysfunction. These findings support the potential of EAF as a therapeutic candidate for AD prevention and management. Graphical Abstract Schematic representation summarising the mechanisms underlying the neuroprotective effects of Elaeocarpus angustifolius alkaloid-rich fraction (EAF) in AlCl₃-induced rat model of AD
- Open Access
- 24 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (48) , 57876-57888
AI-Driven Quantitative Metabolomics for Early and Precise HIE Diagnosis: Challenges and Solutions
Adequate cerebral oxygenation is vital for neonatal survival and the establishment of a healthy brain function. A disruption in this critical balance, particularly during the perinatal period, can result in hypoxic-ischemic encephalopathy (HIE)a severe and potentially fatal form of neonatal brain injury caused by diminished oxygen and blood flow to the brain. HIE is a major contributor to neonatal morbidity and mortality worldwide, with an even greater burden in low-resource settings, where delays in diagnosis and limited access to timely intervention exacerbate long-term neurodevelopmental outcomes. Affected neonates frequently suffer from a spectrum of sequelae, including cerebral palsy, epilepsy, intellectual disability, and other persistent neurological impairments. Currently, therapeutic hypothermia (TH) is the standard-of-care neuroprotective intervention for moderate to severe HIE. However, its efficacy is highly time-dependent and constrained by the critical need for early and accurate diagnosis often within the first 6 h of life. Traditional diagnostic modalities, including clinical assessment, serum protein biomarkers, electroencephalography (EEG), and neuroimaging, frequently lack the sensitivity and specificity required for early risk stratification, thereby limiting their clinical utility during this narrow therapeutic window. In this context, metabolomics-based approaches have emerged as powerful tools to detect subtle early biochemical changes associated with neuronal injury and energy failure. Biomarkers such as lactate, glutamate, succinate, S-100 protein, and CK-BB have shown potential in reflecting metabolic disturbances characteristic of the HIE. Recent advances in nuclear magnetic resonance (NMR) spectroscopy, when integrated with artificial intelligence (AI)-based pattern recognition algorithms, have further enabled the identification of complex metabolic signatures that are both disease-specific and prognostically informative. Despite their promise, the clinical translation of metabolomics-derived biomarkers remains limited by significant preanalytical variability, particularly in sample handling, processing, and storage conditions. Factors such as anticoagulant type, temperature fluctuations, and delays in sample processing can profoundly alter metabolite stability, leading to inconsistent results and reduced reproducibility across cohorts. To address these limitations, this review highlights common pitfalls in blood-based metabolomics workflows and presents a novel, rigorously standardized, multipanel metabolomics strategy for HIE evaluation. By coupling high-resolution NMR spectroscopy with machine learning techniques, we propose the development of a composite “Metabolic Index of Brain Health” that quantitatively captures the extent and severity of hypoxic-ischemic injury. This approach not only enhances diagnostic precision but also enables early risk stratification, paving the way for timely therapeutic interventions.
- 24 November 2025
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 10 (48) , 57876-57888
Open AccessAI-Driven Quantitative Metabolomics for Early and Precise HIE Diagnosis: Challenges and Solutions
Adequate cerebral oxygenation is vital for neonatal survival and the establishment of a healthy brain function. A disruption in this critical balance, particularly during the perinatal period, can result in hypoxic-ischemic encephalopathy (HIE)a severe and potentially fatal form of neonatal brain injury caused by diminished oxygen and blood flow to the brain. HIE is a major contributor to neonatal morbidity and mortality worldwide, with an even greater burden in low-resource settings, where delays in diagnosis and limited access to timely intervention exacerbate long-term neurodevelopmental outcomes. Affected neonates frequently suffer from a spectrum of sequelae, including cerebral palsy, epilepsy, intellectual disability, and other persistent neurological impairments. Currently, therapeutic hypothermia (TH) is the standard-of-care neuroprotective intervention for moderate to severe HIE. However, its efficacy is highly time-dependent and constrained by the critical need for early and accurate diagnosis often within the first 6 h of life. Traditional diagnostic modalities, including clinical assessment, serum protein biomarkers, electroencephalography (EEG), and neuroimaging, frequently lack the sensitivity and specificity required for early risk stratification, thereby limiting their clinical utility during this narrow therapeutic window. In this context, metabolomics-based approaches have emerged as powerful tools to detect subtle early biochemical changes associated with neuronal injury and energy failure. Biomarkers such as lactate, glutamate, succinate, S-100 protein, and CK-BB have shown potential in reflecting metabolic disturbances characteristic of the HIE. Recent advances in nuclear magnetic resonance (NMR) spectroscopy, when integrated with artificial intelligence (AI)-based pattern recognition algorithms, have further enabled the identification of complex metabolic signatures that are both disease-specific and prognostically informative. Despite their promise, the clinical translation of metabolomics-derived biomarkers remains limited by significant preanalytical variability, particularly in sample handling, processing, and storage conditions. Factors such as anticoagulant type, temperature fluctuations, and delays in sample processing can profoundly alter metabolite stability, leading to inconsistent results and reduced reproducibility across cohorts. To address these limitations, this review highlights common pitfalls in blood-based metabolomics workflows and presents a novel, rigorously standardized, multipanel metabolomics strategy for HIE evaluation. By coupling high-resolution NMR spectroscopy with machine learning techniques, we propose the development of a composite “Metabolic Index of Brain Health” that quantitatively captures the extent and severity of hypoxic-ischemic injury. This approach not only enhances diagnostic precision but also enables early risk stratification, paving the way for timely therapeutic interventions.
- Open Access
- 25 September 2025
- Published by Deep Science Publishing
- p. 178-208
Theranostic Nanoparticles-Dual Function Platform for Diagnosis & Treatment in Alzheimer’s disease
Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders, marked by progressive memory loss, cognitive decline, and irreversible neuronal damage. Traditional approaches to AD diagnosis and treatment face major limitations—late detection, poor blood–brain barrier (BBB) penetration, and a lack of real-time treatment monitoring. Theranostic nanoparticles, integrating both therapeutic and diagnostic functions into a single nanoscale platform, offer a groundbreaking solution. These smart carriers can cross the BBB, selectively bind to Alzheimer’s biomarkers such as amyloid-beta plaques and tau tangles, deliver targeted drugs, and simultaneously enable advanced imaging modalities like MRI, PET, and fluorescence for real-time monitoring. By merging early detection with precision drug delivery, theranostic nanoplatforms have the potential to slow or even halt disease progression while minimizing systemic side effects. This chapter explores the design, mechanisms, applications, and clinical potential of theranostic nanoparticles in Alzheimer’s, highlighting their transformative role in the future of personalized neuromedicine.
- 25 September 2025
- Published by Deep Science Publishing
- p. 178-208
Open AccessTheranostic Nanoparticles-Dual Function Platform for Diagnosis & Treatment in Alzheimer’s disease
Alzheimer’s disease (AD) remains one of the most challenging neurodegenerative disorders, marked by progressive memory loss, cognitive decline, and irreversible neuronal damage. Traditional approaches to AD diagnosis and treatment face major limitations—late detection, poor blood–brain barrier (BBB) penetration, and a lack of real-time treatment monitoring. Theranostic nanoparticles, integrating both therapeutic and diagnostic functions into a single nanoscale platform, offer a groundbreaking solution. These smart carriers can cross the BBB, selectively bind to Alzheimer’s biomarkers such as amyloid-beta plaques and tau tangles, deliver targeted drugs, and simultaneously enable advanced imaging modalities like MRI, PET, and fluorescence for real-time monitoring. By merging early detection with precision drug delivery, theranostic nanoplatforms have the potential to slow or even halt disease progression while minimizing systemic side effects. This chapter explores the design, mechanisms, applications, and clinical potential of theranostic nanoparticles in Alzheimer’s, highlighting their transformative role in the future of personalized neuromedicine.
- Open Access
- 9 September 2025
- Published by Deep Science Publishing
- p. 196-219
Nano diagnostics for Early Detection of Breast Cancer: Liquid Biopsy, Biosensors and Imaging
Breast cancer remains a leading cause of illness and death among women worldwide especially in low and middle-income countries where early detection tools are often limited. Although traditional diagnostic methods like mammography, ultrasound, MRI and biopsies have played an essential role in identifying breast cancer, they come with challenges such as invasiveness, high cost, limited sensitivity and difficulty in monitoring disease progression in real time. Nanotechnology offers a transformative solution through nano diagnostics the use of nanoscale tools for early, accurate cancer detection. Techniques like nano enhanced liquid biopsies, biosensors and imaging agents can identify minute cancer markers in body fluids or tissues, allowing for less invasive and more personalized approaches. Nanomaterials such as gold nanoparticles, quantum dots, magnetic particles and graphene oxide enhance sensitivity and speed in diagnostics. These tools enable detection of DNA mutations, cancer proteins and improved imaging clarity with nano-contrast agents. Despite hurdles like regulatory challenges and production costs, ongoing research is advancing the clinical adoption of nano diagnostics. Future developments may include wearable nano sensors and AI-powered digital platforms for real-time monitoring. In summary, nanotechnology is reshaping breast cancer diagnosis enabling earlier, smarter and more accessible care with the potential to improve outcomes and save lives.
- 9 September 2025
- Published by Deep Science Publishing
- p. 196-219
Open AccessNano diagnostics for Early Detection of Breast Cancer: Liquid Biopsy, Biosensors and Imaging
Breast cancer remains a leading cause of illness and death among women worldwide especially in low and middle-income countries where early detection tools are often limited. Although traditional diagnostic methods like mammography, ultrasound, MRI and biopsies have played an essential role in identifying breast cancer, they come with challenges such as invasiveness, high cost, limited sensitivity and difficulty in monitoring disease progression in real time. Nanotechnology offers a transformative solution through nano diagnostics the use of nanoscale tools for early, accurate cancer detection. Techniques like nano enhanced liquid biopsies, biosensors and imaging agents can identify minute cancer markers in body fluids or tissues, allowing for less invasive and more personalized approaches. Nanomaterials such as gold nanoparticles, quantum dots, magnetic particles and graphene oxide enhance sensitivity and speed in diagnostics. These tools enable detection of DNA mutations, cancer proteins and improved imaging clarity with nano-contrast agents. Despite hurdles like regulatory challenges and production costs, ongoing research is advancing the clinical adoption of nano diagnostics. Future developments may include wearable nano sensors and AI-powered digital platforms for real-time monitoring. In summary, nanotechnology is reshaping breast cancer diagnosis enabling earlier, smarter and more accessible care with the potential to improve outcomes and save lives.
- 12 August 2025
- Published by SAGE Publications in Journal of Biomaterials Applications
- Vol. 40 (6) , 650-665
In vitro , ex vivo , and in vivo evaluation of polysaccharide based thermo-sensitive in situ gel for the treatment of glaucoma
One of the disadvantages of traditional ophthalmic formulations is their short residence time in the eye. An in situ gel is recommended as a remedy, as it can be converted into a gel upon contact with the eye and adhere for an extended period. Tamarind seed polysaccharide (TSP) is non thermo-sensitive and possesses the necessary properties to be used as a vehicle for administering medication to the eye. However, the administration of medication into the eyes through TSP based in situ gel has not yet been studied. N -isopropyl acrylamide was grafted onto TSP to make it temperature sensitive. Then, a TSP-based thermo-sensitive in situ gel-forming solution loaded with dorzolamide hydrochloride (2% w/v) was developed and evaluated through in vitro , ex vivo , and in vivo tests. The in situ gel forming solution turns into a gel at 37°C. The safety and efficacy of the formulation were confirmed through an in vivo study on rabbit eyes with induced glaucoma. The findings indicate that the in situ gel significantly reduced intraocular pressure (IOP), with effects comparable to those of marketed eye drops.
- 12 August 2025
- Published by SAGE Publications in Journal of Biomaterials Applications
- Vol. 40 (6) , 650-665
In vitro , ex vivo , and in vivo evaluation of polysaccharide based thermo-sensitive in situ gel for the treatment of glaucoma
One of the disadvantages of traditional ophthalmic formulations is their short residence time in the eye. An in situ gel is recommended as a remedy, as it can be converted into a gel upon contact with the eye and adhere for an extended period. Tamarind seed polysaccharide (TSP) is non thermo-sensitive and possesses the necessary properties to be used as a vehicle for administering medication to the eye. However, the administration of medication into the eyes through TSP based in situ gel has not yet been studied. N -isopropyl acrylamide was grafted onto TSP to make it temperature sensitive. Then, a TSP-based thermo-sensitive in situ gel-forming solution loaded with dorzolamide hydrochloride (2% w/v) was developed and evaluated through in vitro , ex vivo , and in vivo tests. The in situ gel forming solution turns into a gel at 37°C. The safety and efficacy of the formulation were confirmed through an in vivo study on rabbit eyes with induced glaucoma. The findings indicate that the in situ gel significantly reduced intraocular pressure (IOP), with effects comparable to those of marketed eye drops.
- 9 July 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (4) , 1-13
In Vitro Assessment of Cholinesterase Inhibition and Neuroprotective Effects of Elaeocarpus angustifolius Blume Against Amyloid-Beta Peptide-Induced Toxicity in SH-SY5Y and BV-2 Cells
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder primarily characterized by memory impairment and cognitive decline. Pathophysiological mechanisms contributing to AD include oxidative stress, increased acetylcholinesterase activity, neuroinflammation, and the accumulation of hyperphosphorylated tau proteins and amyloid-β (Aβ) plaques in the brain. The shortcomings of existing therapeutic approaches have necessitated the exploration of alternative treatment strategies. Elaeocarpus angustifolius Blume, traditionally used for neurological disorders, has been investigated for its neuroprotective potential through its alkaloid-rich fraction. This study evaluated the acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of E. angustifolius alkaloid-rich fraction (EAF) and its protective effects against Aβ1−42-induced cytotoxicity in human neuron-like SH-SY5Y cells and murine microglial BV-2 cells using the MTT assay. The results demonstrated that for AChE and BuChE, EAF showed significant inhibition with IC50 of 145.1 ± 4.782 µg/mL and 165.8 ± 1.10 µg/mL, respectively. In the MTT assay, EAF effectively mitigated Aβ1−42-induced cytotoxicity in a dose-dependent manner, with the highest dose (100 µg/mL) restoring viability from 67.91 to 75.31% in SH-SY5Y cells and from 60.29 to 76.01% in BV-2 cells. From these results, it is apparent that EAF has anticholinesterase and neuroprotective properties. However, further research on this may help decipher underlying mechanisms before establishing EAF as an effective alternative in treating AD.
- 9 July 2025
- Published by Springer Nature in Neurochemical Research
- Vol. 50 (4) , 1-13
In Vitro Assessment of Cholinesterase Inhibition and Neuroprotective Effects of Elaeocarpus angustifolius Blume Against Amyloid-Beta Peptide-Induced Toxicity in SH-SY5Y and BV-2 Cells
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder primarily characterized by memory impairment and cognitive decline. Pathophysiological mechanisms contributing to AD include oxidative stress, increased acetylcholinesterase activity, neuroinflammation, and the accumulation of hyperphosphorylated tau proteins and amyloid-β (Aβ) plaques in the brain. The shortcomings of existing therapeutic approaches have necessitated the exploration of alternative treatment strategies. Elaeocarpus angustifolius Blume, traditionally used for neurological disorders, has been investigated for its neuroprotective potential through its alkaloid-rich fraction. This study evaluated the acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of E. angustifolius alkaloid-rich fraction (EAF) and its protective effects against Aβ1−42-induced cytotoxicity in human neuron-like SH-SY5Y cells and murine microglial BV-2 cells using the MTT assay. The results demonstrated that for AChE and BuChE, EAF showed significant inhibition with IC50 of 145.1 ± 4.782 µg/mL and 165.8 ± 1.10 µg/mL, respectively. In the MTT assay, EAF effectively mitigated Aβ1−42-induced cytotoxicity in a dose-dependent manner, with the highest dose (100 µg/mL) restoring viability from 67.91 to 75.31% in SH-SY5Y cells and from 60.29 to 76.01% in BV-2 cells. From these results, it is apparent that EAF has anticholinesterase and neuroprotective properties. However, further research on this may help decipher underlying mechanisms before establishing EAF as an effective alternative in treating AD.
- 1 October 2021
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 18 (5) , 497-507
Combination of Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Agonist and PPAR Gamma Co-Activator 1α (PGC-1α) Activator Ameliorates Cognitive Deficits, Oxidative Stress, and Inflammation in Rodent Model of Parkinson’s Disease
Background: PPAR gamma co-activator 1α (PGC-1α) is known as the master regulator of mitochondrial biogenesis. It is also a co-activator of peroxisome proliferator-activated receptor-gamma (PPARγ) and plays a role in preventing mitochondrial dysfunction in several neurodegenerative disorders, including Parkinson’s disease (PD). Depletion in the levels of these proteins has been linked to oxidative stress, inflammation, and DNA damage, all of which are known to contribute to the pathogenesis of PD. Objective: In the present study, combination therapy of PPARγ agonist (GW1929) and PGC-1α activator (alpha-lipoic acid) was employed to ameliorate cognitive deficits, oxidative stress, and inflammation associated with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. Results: Our study showed that MPTP-induced PD rats exhibited an increase in oxidative stress and inflammation, leading to cognitive deficits. Furthermore, MPTP-induced PD rats also exhibited reduced mitochondrial biogenesis in comparison to control and sham animals. Intraperitoneal administration of GW 1929 and alpha-lipoic acid in doses lower than those earlier reported individually in literature led to an improvement in the cognitive deficits in comparison to MPTP-induced PD rats. These improvements were accompanied by a reduction in the levels of oxidative stress and inflammation. In addition, an increase in mitochondrial biogenesis was also observed after the combination of these pharmacological agents. Conclusion: Our results provide a rationale for the development of agents targeting PPARγ and PGC-1α as potent therapeutics for the treatment of neurological diseases like PD.
- 1 October 2021
- Published by Bentham Science Publishers Ltd. in Current Neurovascular Research
- Vol. 18 (5) , 497-507
Combination of Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Agonist and PPAR Gamma Co-Activator 1α (PGC-1α) Activator Ameliorates Cognitive Deficits, Oxidative Stress, and Inflammation in Rodent Model of Parkinson’s Disease
Background: PPAR gamma co-activator 1α (PGC-1α) is known as the master regulator of mitochondrial biogenesis. It is also a co-activator of peroxisome proliferator-activated receptor-gamma (PPARγ) and plays a role in preventing mitochondrial dysfunction in several neurodegenerative disorders, including Parkinson’s disease (PD). Depletion in the levels of these proteins has been linked to oxidative stress, inflammation, and DNA damage, all of which are known to contribute to the pathogenesis of PD. Objective: In the present study, combination therapy of PPARγ agonist (GW1929) and PGC-1α activator (alpha-lipoic acid) was employed to ameliorate cognitive deficits, oxidative stress, and inflammation associated with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. Results: Our study showed that MPTP-induced PD rats exhibited an increase in oxidative stress and inflammation, leading to cognitive deficits. Furthermore, MPTP-induced PD rats also exhibited reduced mitochondrial biogenesis in comparison to control and sham animals. Intraperitoneal administration of GW 1929 and alpha-lipoic acid in doses lower than those earlier reported individually in literature led to an improvement in the cognitive deficits in comparison to MPTP-induced PD rats. These improvements were accompanied by a reduction in the levels of oxidative stress and inflammation. In addition, an increase in mitochondrial biogenesis was also observed after the combination of these pharmacological agents. Conclusion: Our results provide a rationale for the development of agents targeting PPARγ and PGC-1α as potent therapeutics for the treatment of neurological diseases like PD.
- 26 August 2021
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 40 (9) , 2382-2383
Reply to Comment on Plugge et al. “Toward a Universal Acute Fish Threshold of Toxicological Concern”
- 26 August 2021
- Published by Oxford University Press (OUP) in Environmental Toxicology and Chemistry
- Vol. 40 (9) , 2382-2383
Reply to Comment on Plugge et al. “Toward a Universal Acute Fish Threshold of Toxicological Concern”